Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus

Apr 27, 2002Neurogastroenterology and motility

Pramlintide’s effects on stomach emptying in type 1 and type 2 diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Pramlintide delays gastric emptying by 177 minutes compared to placebo in individuals with type 1 or type 2 diabetes.

Gastric emptying times were significantly longer with pramlintide at doses of 30 microg (268 minutes) and 60 microg (329 minutes) compared to the placebo (91 minutes).
Postprandial pancreatic polypeptide levels were reduced in response to both 30 and 60 microg doses of pramlintide compared to placebo.
No significant differences in gastric emptying or pancreatic polypeptide levels were observed between type 1 and type 2 diabetic subjects.
Pramlintide's effects on gastric emptying occur in diabetic individuals without clinically detected complications.
Further research is necessary to explore pramlintide's effects in patients with impaired gastric motor function.

AI simplified

Pramlintide delays gastric emptying, possibly by a centrally mediated mechanism. Our aim was to determine whether the effects of pramlintide on gastric emptying differ in people with type 1 or type 2 diabetes who had no history of complications. Using a randomized, three-period, two-dose, crossover design, we studied the effects of 0, 30, or 60 microg t.i.d. pramlintide subcutaneously for 5 days each in six type 1 and six type 2 diabetic subjects. Gastric emptying of solids was measured by 13C-Spirulina breath test. Plasma pancreatic polypeptide (HPP) response to the test meal was also measured. Relative to placebo [t 50% 91 +/- 6 min (means +/- SEM)], pramlintide equally delayed gastric emptying following 30 or 60 microg t.i.d. (268 +/- 37 min, 329 +/- 49 min, respectively; P < 0.01]. Postprandial HPP levels were lower in response to 30 and 60 microg pramlintide compared to placebo. There were no significant differences in the effects on gastric emptying or HPP levels between type 1 and type 2 diabetic subjects. Pramlintide delays gastric emptying in diabetes unassociated with clinically detected complications. Further studies are needed in diabetic patients with impaired gastric motor function.

Full Text

Full text is available at the source.

View full text ↗

Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief